Search BRNS
Barinthus Biotherapeutics plc.
Nasdaq · CIK 1828185
Last close0.74
Daily changen/a
10 Years gain-94.75%
Dividends TTM0
Dividend yieldn/a
Fundamental Analysis
BRNS · STANDARD
SIC 2834 · Pharmaceutical Preparations · Fiscal year end 1231
Fundamental
44.6Momentum
n/aAcceleration
n/aConfidence
63.0Annual Revenue6
Quarterly Revenue18
Annual CFO6
Balance SheetAvailable
RankingEligible
Score Breakdown
Growth12.5 / 25
Quality12.5 / 25
Capital Efficiency0.0 / 20
Balance Sheet15.0 / 15
Shareholder Economics2.4 / 10
Forward Indicators0.0 / 5
Signals
Net debt reductionNet debt declined versus the comparison period.
Key Metrics
Revenue Growth TTM1,766.46%OK
Revenue CAGR 3Yn/aINSUFFICIENT_HISTORY
Gross Marginn/aMISSING
Operating Marginn/aMISSING
FCF Marginn/aMISSING
FCF Growthn/aINSUFFICIENT_HISTORY
ROICn/aMISSING
Incremental Operating Margin 3Yn/aNOT_MEANINGFUL
Net Debt / CFOn/aNOT_MEANINGFUL
Diluted Share Growth 1Yn/aINSUFFICIENT_HISTORY
SBC / Revenuen/aMISSING
SBC / FCFn/aNOT_MEANINGFUL
Financial History
| Period | Revenue | Gross Profit | Operating Income | CFO | FCF | Gross Margin | Op Margin | FCF Margin | ROIC | Shares |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 FY Dec 31, 2025 | $0.00 | $506,000.00 | -$70.56M | -$47.98M | -$48.02M | n/a | n/a | n/a | -482.19% | 40.53M |
| 2025 FY Dec 31, 2024 | $14.97M | $16.15M | -$67.97M | -$28.94M | -$29.83M | 107.86% | -454.07% | -199.29% | -167.64% | 39.35M |
| 2024 FY Dec 31, 2023 | $802,000.00 | $802,000.00 | -$83.91M | -$50.93M | -$56.34M | 100% | -10,463.09% | -7,024.69% | -142.25% | 38.39M |
| 2023 FY Dec 31, 2022 | $44.70M | $44.70M | -$4.04M | -$14.43M | -$20.57M | 100% | -9.04% | -46.01% | -6.06% | 38.17M |
| 2022 FY Dec 31, 2021 | $268,000.00 | $268,000.00 | -$45.22M | -$32.58M | -$33.73M | 100% | -16,873.51% | -12,585.45% | n/a | 25.89M |
Formula Trace
| Metric | Value | Formula | Status | Source |
|---|---|---|---|---|
| Revenue TTM | $14.97M | sum latest 4 fiscal quarters Revenue | OK | 0001828185-24-000036, 0001828185-24-000075 |
| Revenue Growth TTM | 1,766.46% | Revenue_TTM / Revenue_TTM_1Y_ago - 1 | OK | 0001828185-24-000036, 0001828185-24-000075 |
| Revenue CAGR 3Y | n/a | (Revenue_current / Revenue_3Y_ago)^(1/3) - 1 | INSUFFICIENT_HISTORY | 0001828185-26-000012 |
| Revenue CAGR 5Y | n/a | (Revenue_current / Revenue_5Y_ago)^(1/5) - 1 | INSUFFICIENT_HISTORY | 0001828185-26-000012 |
| Gross Profit CAGR 3Y | -77.55% | (GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1 | OK | 0001828185-26-000012 |
| Operating Income Growth | n/a | OperatingIncome_current / OperatingIncome_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| FCF Growth | n/a | FCF_current / FCF_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| Revenue Growth Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Profit Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Income Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| FCF Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Net Debt / CFO | n/a | Net Debt / CFO | NOT_MEANINGFUL | 0001828185-25-000072 |
| Current Ratio | 8.04x | Current Assets / Current Liabilities | OK | derived |
| Revenue per Diluted Share | $0.37 | Revenue / Diluted Shares | OK | 0001828185-24-000036, 0001828185-24-000075 |
| SBC / FCF | n/a | SBC / FCF | NOT_MEANINGFUL | derived |
| Dividend Payout Ratio | n/a | Cash dividends paid / Net income | NOT_MEANINGFUL | 0001828185-26-000012 |
| Diluted EPS TTM | n/a | Net income TTM / Diluted shares | NOT_MEANINGFUL | 0001828185-25-000072 |
| Gross Margin Delta 1Y | n/a | GrossMargin_current - GrossMargin_prior_year | INSUFFICIENT_HISTORY | derived |